Slayback Pharma Revenue and Competitors

Claim your profile

Location

$110M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Slayback Pharma's estimated annual revenue is currently $21.1M per year.(i)
  • Slayback Pharma received $60.0M in venture funding in January 2017.
  • Slayback Pharma's estimated revenue per employee is $201,000
  • Slayback Pharma's total funding is $110M.

Employee Data

  • Slayback Pharma has 105 Employees.(i)
  • Slayback Pharma grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4180M1730013%$550MN/A
#2
$4.8M24-23%N/AN/A
#3
N/A3590%$70MN/A
#4
$8.2M41-2%N/AN/A
#5
$38500M914242%N/AN/A
#6
$34.4M171N/AN/AN/A
#7
$34.8M173-14%N/AN/A
#8
$40.6M202-11%N/AN/A
#9
$5.4M27N/AN/AN/A
#10
$0.4M2N/AN/AN/A

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.

keywords:N/A

$110M

Total Funding

105

Number of Employees

$21.1M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Slayback Pharma News

2022-04-17 - Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

Eagle previously asserted several Orange Book-listed patents against Slayback Pharma LLC, Apotex Inc. (“Apotex”) et al, Mylan Laboratories...

2022-04-06 - Lupin launches Merzee Capsules in the United States

Slayback Pharma is a Princeton, NJ headquartered, speciality pharmaceutical company focused on the development and commercialization of...

2022-03-22 - Slayback Pharma to invest $20m in expansion in Hyderabad

HYDERABAD: The Telangana government on Sunday said US-based complex generic and specialty drugs player, Slayback Pharma, will be investing...

2021-06-25 - Slayback Appoints Pete Meyers as Chief Financial Officer

PRINCETON, N.J., June 25, 2021 /PRNewswire/ -- Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced today the appointment of Pete A. Meyers as its Chief Financial Officer. Pete has nearly three decades of rich experience in the pharmaceutical industry straddl ...

2021-02-04 - Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla®

PRINCETON, N.J., Feb. 4, 2021 /PRNewswire/ -- Slayback Pharma LLC announces that it has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg and fulfilled customer orders for the product. With the launch, Slayback has effectively secu ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A1055%N/A
#2
$18.9M1050%N/A
#3
$16M110-4%N/A
#4
$24.4M111-2%N/A
#5
$28.4M113-2%N/A

Slayback Pharma Funding

DateAmountRoundLead InvestorsReference
2017-01-06$60.0MUndisclosedKKRArticle